Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072569
Filing Date
2025-05-15
Accepted
2025-05-15 16:05:27
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fbrx-20250331.htm   iXBRL 10-Q 1790045
2 EX-10.1 fbrx-ex10_1.htm EX-10.1 461850
3 EX-10.2 fbrx-ex10_2.htm EX-10.2 24480
4 EX-10.3 fbrx-ex10_3.htm EX-10.3 101456
5 EX-10.4 fbrx-ex10_4.htm EX-10.4 71838
6 EX-31.1 fbrx-ex31_1.htm EX-31.1 17183
7 EX-31.2 fbrx-ex31_2.htm EX-31.2 16885
8 EX-32.1 fbrx-ex32_1.htm EX-32.1 10076
9 EX-32.2 fbrx-ex32_2.htm EX-32.2 10117
  Complete submission text file 0000950170-25-072569.txt   7698169

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fbrx-20250331.xsd EX-101.SCH 1016957
69 EXTRACTED XBRL INSTANCE DOCUMENT fbrx-20250331_htm.xml XML 1069507
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38052 | Film No.: 25952675
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)